Additionally, the study examined the incidence of ESBLE and CIPRE in
baseline Enterobacteriaceae isolates in North America (NA), South America
(SA), and Europe (EU). To evaluate these levels, minimum inhibitory
concentrations (MICs) were determined for ESBLE and CIPRE. ESBLE were
determined as Enterobacteriaceae that included Escherichia coli, Klebsiella
spp., and Proteus spp. with ceftazidime MICs greater than or equal to 2
micrograms/mL. CIPRE were defined as Enterobacteriaceae with ciprofloxacin
MIC greater than or equal to 4 micrograms/mL. The study results showed:
-- Relative incidence of ESBLE was highest in Europe (8% of all
Enterobacteriaceae), and the relative incidence of CIPRE was highest in
South America (16%).
-- In ESBLE from all regions combined, 68% were resistant to ciprofloxacin,
while 98% had doripenem MICs less than or equal to 2 micrograms/mL.
-- In CIPRE from all regions combined, 99% had carbapenem MICs less than or
equal to 4 micrograms/mL.
A second study, also presented at the 2008 ICAAC/IDSA Joint Meeting, that examined stored clinical Enterobacteriaceae isolates, found that overall susceptibility (less than or equal to 0.5 micrograms/mL) for doripenem among Enterobacteriaceae strains were 98.9% and 96.5% for strains expressing ESBL and AmpC Beta-lactamase enzymes, respectively. Both ESBL and AmpC Beta-lactamase are enzymes that destroy cephalosporins and other related antibiotics. Approximately, 32,990 Enterobacteriaceae isolates in four geographic locations (North America, Latin America, Europe and Asia-Pacific) were recovered from more than 60 medical centers, which participated in the global doripenem surveillance program from 2003 to 2007.
In this study, susceptibility testing was performed by the monitoring
laboratory using Clinical and Laboratory Standards Institute (CLSI) methods
and interpretive c
|SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.|
Copyright©2008 PR Newswire.
All rights reserved